Chimeric Therapeutics Limited (CHMMF)
Sector: Biotechnology
Industry: Biotechnology
Chimeric Therapeutics Limited
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 12, 2026 | 0.1000 | 0.1000 | 0.1000 | 0.1000 | 30,000 |
| Nov 9, 2026 | 0.1000 | 0.1000 | 0.1000 | 0.1000 | 30,000 |
| Nov 6, 2026 | 0.1000 | 0.1000 | 0.1000 | 0.1000 | 30,000 |
| Nov 3, 2026 | 0.1000 | 0.1000 | 0.1000 | 0.1000 | 30,000 |
| Nov 2, 2026 | 0.1000 | 0.1000 | 0.1000 | 0.1000 | 30,000 |
| Oct 30, 2026 | 0.1000 | 0.1000 | 0.1000 | 0.1000 | 30,000 |
| Oct 29, 2026 | 0.1000 | 0.1000 | 0.1000 | 0.1000 | 30,000 |
| Oct 26, 2026 | 0.1000 | 0.1000 | 0.1000 | 0.1000 | 30,000 |
| Oct 23, 2026 | 0.1000 | 0.1000 | 0.1000 | 0.1000 | 30,000 |
| Oct 20, 2026 | 0.1000 | 0.1000 | 0.1000 | 0.1000 | 30,000 |
| Oct 19, 2026 | 0.1000 | 0.1000 | 0.1000 | 0.1000 | 30,000 |
| Oct 16, 2026 | 0.1000 | 0.1000 | 0.1000 | 0.1000 | 30,000 |
| Oct 15, 2026 | 0.1000 | 0.1000 | 0.1000 | 0.1000 | 30,000 |
| Oct 12, 2026 | 0.1000 | 0.1000 | 0.1000 | 0.1000 | 30,000 |
| Oct 9, 2026 | 0.1000 | 0.1000 | 0.1000 | 0.1000 | 30,000 |
| Oct 6, 2026 | 0.1000 | 0.1000 | 0.1000 | 0.1000 | 30,000 |
| Oct 5, 2026 | 0.1000 | 0.1000 | 0.1000 | 0.1000 | 30,000 |
Chimeric Therapeutics Limited is an Australian biotechnology firm operating at the clinical stage, dedicated to advancing and commercializing a diverse portfolio of cell-based treatments specifically for cancer.
Its pipeline features several promising candidates. CHM 0201, utilizing a core natural killer (NK) cell platform, is currently undergoing Phase I clinical trials for the treatment of both solid tumors and hematological malignancies. Another key program, CHM 1101 (a CLTX CAR T-cell therapy), is also in Phase I development, specifically targeting patients with recurrent or progressive glioblastoma that expresses MMP2. Beyond these lead programs, the company is actively developing a range of other innovative therapies. These include CHM 0301 for various blood cancers; CHM 1301 (CLTX CAR NK) and CHM 2301 (CDH17 CAR NK), both designed to combat solid tumors. The CLTX CAR T-cell therapy, CHM 1101, is additionally being explored for indications such as melanoma, colorectal, and prostate cancers. Furthermore, CHM 2101 (CDH17 CAR T) is under development for neuroendocrine, colorectal, pancreatic, and gastric cancers. Established in 2020, Chimeric Therapeutics Limited maintains its headquarters in Carlton, Australia.
based on 41.04M shares outstanding
30d Avg
30.00K
60d Avg
30.00K
90d Avg
30.00K